Strikingly, those patients bearing a CCA with low IL-6 in fibroblasts and a high LC3 and low p62 pattern in cancer cells (L/H/L) were the ones most benefiting from the adjuvant chemotherapy. The gene discussed is MAP1LC3A; the disease is cancer.